GLP-1 Receptor Agonists in Anesthesia: Bridging Delayed Gastric Emptying, Aspiration Risk, and Practical Management

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and the dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist tirzepatide are now prescribed widely for type 2 diabetes and obesity. Because these drugs slow gastric emptying, they have been linked to retained gastric contents despite fasting and, in case reports, to pulmonary aspiration. Early guidance advised holding the drugs before elective procedures, whereas later consensus statements advised continuing them with mitigation. This narrative review addresses how much, and for how long, these agents delay gastric emptying; whether they increase residual gastric content and pulmonary aspiration; and what the anesthesiologist should do. Physiologic studies show a measurable delay whose attenuation with prolonged treatment is disputed. Most observational studies and all four meta-analyses that pooled residual content found more residual gastric content in users. Most large cohort studies and meta-analyses did not find an increase in pulmonary aspiration; one endoscopy cohort and one elective-surgery study, both known here only as reported in other sources, did, and the certainty of the evidence is low. A randomized trial of holding one dose versus continuing, an interim analysis stopped early in sedated endoscopy, found less clinically significant residual gastric volume with holding, but it was not powered to detect aspiration. We close with a practical framework for identifying patients, stratifying risk, deciding about the drug, diet, assessing gastric content and planning the airway; it rests largely on consensus statements and expert opinion, because no trial has tested a fasting or airway strategy against aspiration outcomes.

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-22
DOI
https://doi.org/10.5281/zenodo.24430848
Primary Topic
Diabetes Treatment and Management
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

GLP-1 Receptor Agonists in Anesthesia: Bridging Delayed Gastric Emptying, Aspiration Risk, and Practical Management

Salman Mashary Alharbi, Abdulrahman Fahad Almusallam
Zenodo (CERN European Organization for Nuclear Research)
Diabetes Treatment and Management
preprint

GLP-1 Receptor Agonists in Anesthesia: Bridging Delayed Gastric Emptying, Aspiration Risk, and Practical Management

Salman Mashary Alharbi, Abdulrahman Fahad Almusallam
preprint en

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and the dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist tirzepatide are now prescribed widely for type 2 diabetes and obesity. Because these drugs slow gastric emptying, they have been linked to retained gastric contents despite fasting and, in case reports, to pulmonary aspiration. Early guidance advised holding the drugs before elective procedures, whereas later consensus statements advised continuing them with mitigation. This narrative review addresses how much, and for how long, these agents delay gastric emptying; whether they increase residual gastric content and pulmonary aspiration; and what the anesthesiologist should do. Physiologic studies show a measurable delay whose attenuation with prolonged treatment is disputed. Most observational studies and all four meta-analyses that pooled residual content found more residual gastric content in users. Most large cohort studies and meta-analyses did not find an increase in pulmonary aspiration; one endoscopy cohort and one elective-surgery study, both known here only as reported in other sources, did, and the certainty of the evidence is low. A randomized trial of holding one dose versus continuing, an interim analysis stopped early in sedated endoscopy, found less clinically significant residual gastric volume with holding, but it was not powered to detect aspiration. We close with a practical framework for identifying patients, stratifying risk, deciding about the drug, diet, assessing gastric content and planning the airway; it rests largely on consensus statements and expert opinion, because no trial has tested a fasting or airway strategy against aspiration outcomes.

Zenodo (CERN European Organization for Nuclear Research)
King Saud University (SA)
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon